SLC9A2 and neoplasm: Furthermore, analysis of tumor-infiltrating immune cells revealed increased CD8+ TILs in both the OE-Slc9a2 + anti-PD-1 and bevacizumab + anti-PD-1 groups (Fig. 7K).